enGene Stock Crashes After Bladder Cancer Drug Shows Solid Safety but Disappointing Durability
enGene bladder cancer drug shows good safety and early response, but weak long-term results; stock drops ~66% after update.
/ 3 items
#ENGN↓
Wall Street Starts Coverage on PLSE and ENGN: What You Need to Know
Mizuho and Jefferies initiate coverage on Pulse Biosciences and enGene, highlighting growth potential, strong clinical data, and upcoming catalysts in biotech.
enGene Upgraded to Strong Buy on Promising Bladder Cancer Data
Raymond James upgrades enGene to Strong Buy with $27 target as detalimogene shows 62% complete response rate in bladder cancer trial with excellent tolerability.